{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(18)"],"submitter":["Stephan P"],"pubmed_abstract":["<h4>Abstract</h4>Anti-CD19 chimeric antigen receptor (CAR) T cells have shown impressive results in the treatment of relapsed/refractory aggressive large B-cell lymphomas (LBCLs). However, the prognostic value of the LBCL histological subtype in the context of CAR T-cell therapy is unclear. Here, we report the prognostic value of transformed indolent non-Hodgkin lymphoma (TriNHL; N = 110) confirmed by an expert pathological review (LYMPHOPATH) vs de novo LBCL (N = 391) in the context of CAR T-cell therapy from 4 centers of the French DESCAR-T registry. After 1:1 propensity score matching (n = 170, 85 patients with TriNHL and 85 patients with de novo LBCL), the median follow-up was 19.4 months (95% confidence interval [CI], 12.0-25.1) for patients with TriNHL and 18.5 months (95% CI, 13.8-2"],"journal":["Blood advances"],"pagination":["4693-4704"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12466217"],"repository":["biostudies-literature"],"pubmed_title":["TRANSCAR: real-world outcomes of CD19 CAR T-cell therapy in relapsed/refractory transformed indolent lymphomas."],"pmcid":["PMC12466217"],"pubmed_authors":["Parrens M","Le Gouill S","Sesques P","Di Blasi R","Galtier J","Stephan P","Houot R","Meignin V","Poullot E","Gros FX","Thieblemont C","Marquet A","Donzel M","Roulin L","Dupont V","Calvani J","Traverse-Glehen A","Lemonnier F","Bachy E"],"additional_accession":[]},"is_claimable":false,"name":"TRANSCAR: real-world outcomes of CD19 CAR T-cell therapy in relapsed/refractory transformed indolent lymphomas.","description":"<h4>Abstract</h4>Anti-CD19 chimeric antigen receptor (CAR) T cells have shown impressive results in the treatment of relapsed/refractory aggressive large B-cell lymphomas (LBCLs). However, the prognostic value of the LBCL histological subtype in the context of CAR T-cell therapy is unclear. Here, we report the prognostic value of transformed indolent non-Hodgkin lymphoma (TriNHL; N = 110) confirmed by an expert pathological review (LYMPHOPATH) vs de novo LBCL (N = 391) in the context of CAR T-cell therapy from 4 centers of the French DESCAR-T registry. After 1:1 propensity score matching (n = 170, 85 patients with TriNHL and 85 patients with de novo LBCL), the median follow-up was 19.4 months (95% confidence interval [CI], 12.0-25.1) for patients with TriNHL and 18.5 months (95% CI, 13.8-2","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-06-03T21:24:10.365Z","creation":"2026-05-01T03:11:11.282Z"},"accession":"S-EPMC12466217","cross_references":{"pubmed":["40311067"],"doi":["10.1182/bloodadvances.2025015834"]}}